Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
Improving product mix
Peak contribution to net sales from launches
in USD
Last five years
Launch of three
31%
additional Biosimilars
Next five years
35%
molecules
31%
1.6bn
49%
69%
3.0bn 51%
69%
Launch of ~190 unique
Generics products¹
65%
2022
Biosimilars
Generics
Complex Generics
Standard Generics
Note: In USD; 1. Product defined as unique combination of molecule and dosage form.
15
Management Presentation
2027
Launch of four key
high-value Biosimilars
Planned launch of
>120 generics products¹
Significant increase in
launch value product
with high focus on LoE
launches and complex
Generics assets
SANDOZView entire presentation